BACKGROUND: The objectives of this study was to investigate if concomitant tricuspid valve repair in patients undergoing continuous flow left ventricular assist device (LVAD) implantation has an impact on the outcome regarding survival and adverse events. METHODS: Between June 2007 and February 2018, 124 consecutive patients received HeartMate II (HMII) [74 (59.7%)] HeartWare (HVAD) [16 (12.9%)], or HeartMate III (HM III) [34 (27.4%)] for end-stage heart failure. Mean age was 63.5±10.9 years. Two 18-patient groups were identified; with [tricuspid valve reconstruction (TVR)] group and without (non-TVR group) accompanying TVR. The primary endpoint was overall survival after device implantation. Secondary endpoints were adverse events during the follow-up period. RESULTS: Survival was not significantly different between the groups (P>0.05). In TVR group, there was a higher need for open chest after surgery and a prolonged inotrope use because of right heart failure (RHF), a higher incidence of acute kidney dysfunction requiring dialysis, as well as a higher need for packed red blood cells due to postoperative bleeding (P<0.05). CONCLUSIONS: In this cohort of patients, LVAD implantation with a concurrent tricuspid valve repair appears to have a worse outcome regarding RHF, bleeding tendency and renal dysfunction (P<0.05). However, the survival was comparable in both TVR and Non-TVR groups (P>0.05).
BACKGROUND: The objectives of this study was to investigate if concomitant tricuspid valve repair in patients undergoing continuous flow left ventricular assist device (LVAD) implantation has an impact on the outcome regarding survival and adverse events. METHODS: Between June 2007 and February 2018, 124 consecutive patients received HeartMate II (HMII) [74 (59.7%)] HeartWare (HVAD) [16 (12.9%)], or HeartMate III (HM III) [34 (27.4%)] for end-stage heart failure. Mean age was 63.5±10.9 years. Two 18-patient groups were identified; with [tricuspid valve reconstruction (TVR)] group and without (non-TVR group) accompanying TVR. The primary endpoint was overall survival after device implantation. Secondary endpoints were adverse events during the follow-up period. RESULTS: Survival was not significantly different between the groups (P>0.05). In TVR group, there was a higher need for open chest after surgery and a prolonged inotrope use because of right heart failure (RHF), a higher incidence of acute kidney dysfunction requiring dialysis, as well as a higher need for packed red blood cells due to postoperative bleeding (P<0.05). CONCLUSIONS: In this cohort of patients, LVAD implantation with a concurrent tricuspid valve repair appears to have a worse outcome regarding RHF, bleeding tendency and renal dysfunction (P<0.05). However, the survival was comparable in both TVR and Non-TVR groups (P>0.05).
Entities:
Keywords:
Left ventricular assist device (LVAD); mechanical circulatory support (MCS); right heart failure (RHF); tricuspid regurgitation; tricuspid valve repair
Authors: Simon Maltais; Yan Topilsky; Vakhtang Tchantchaleishvili; Stephen H McKellar; Lucian A Durham; Lyle D Joyce; Richard C Daly; Soon J Park Journal: J Thorac Cardiovasc Surg Date: 2011-08-11 Impact factor: 5.209
Authors: Nicholas C Dang; Veli K Topkara; Michelle Mercando; Joy Kay; Kurt H Kruger; Michael S Aboodi; Mehmet C Oz; Yoshifumi Naka Journal: J Heart Lung Transplant Date: 2005-12-09 Impact factor: 10.247
Authors: Marius Berman; Steven Tsui; Alain Vuylsteke; Andrew Klein; David P Jenkins Journal: J Heart Lung Transplant Date: 2008-10 Impact factor: 10.247
Authors: Valentino Piacentino; Asvin M Ganapathi; Mark Stafford-Smith; Michael K Hsieh; Chetan B Patel; Alan A Simeone; Joseph G Rogers; Carmelo A Milano Journal: J Thorac Cardiovasc Surg Date: 2012-08-29 Impact factor: 5.209
Authors: Evgenij V Potapov; Martin Schweiger; Alexander Stepanenko; Michael Dandel; Marian Kukucka; Juliane Vierecke; Roland Hetzer; Thomas Krabatsch Journal: ASAIO J Date: 2011 Sep-Oct Impact factor: 2.872
Authors: Valentino Piacentino; Matthew L Williams; Tim Depp; Karla Garcia-Huerta; Laura Blue; Andrew J Lodge; G Burkhard Mackensen; Madhav Swaminathan; Joseph G Rogers; Carmelo A Milano Journal: Ann Thorac Surg Date: 2011-04-01 Impact factor: 4.330
Authors: Diyar Saeed; Trilokesh Kidambi; Shanaz Shalli; Brittany Lapin; S Chris Malaisrie; Richard Lee; William G Cotts; Edwin C McGee Journal: J Heart Lung Transplant Date: 2011-01-06 Impact factor: 10.247
Authors: Evgenij V Potapov; Alexander Stepanenko; Michael Dandel; Marian Kukucka; Hans B Lehmkuhl; Yuguo Weng; Felix Hennig; Thomas Krabatsch; Roland Hetzer Journal: J Heart Lung Transplant Date: 2008-12 Impact factor: 10.247
Authors: Claudio J R Gomez Hamacher; Carolin Torregroza; Najla Sadat; Daniel Scheiber; Jil-Cathrin von der Beek; Ralf Westenfeld; Ivonne Jeanette Knorr; Martin Sager; Artur Lichtenberg; Diyar Saeed Journal: JTCVS Open Date: 2020-09-24
Authors: Alina Zubarevich; Marcin Szczechowicz; Andreas Brcic; Anja Osswald; Konstantinos Tsagakis; Daniel Wendt; Bastian Schmack; Michel Pompeu B O Sá; Jef Van den Eynde; Arjang Ruhparwar; Konstantin Zhigalov Journal: J Cardiothorac Surg Date: 2020-11-16 Impact factor: 1.637